Molecular Glue Discovery Platform

Molecular glue (MG) is a novel class of small molecules that represent a transformative approach in drug discovery. By leveraging the natural ubiquitin-proteasome system (UPS), these compounds act as molecular intermediaries, inducing proximity between target proteins and E3 ligases to facilitate protein degradation. This cutting-edge strategy holds immense promise for treating diseases where traditional small molecule inhibitors or monoclonal antibodies fall short. Our platform specializes in developing molecular glue degraders (MGDs), supported by years of expertise in protein ubiquitination and degradation research. Through advanced screening methods and a proprietary compound library, we aim to identify novel therapeutic targets and deliver groundbreaking solutions in the fight against challenging diseases.

Our Molecular Glue Discovery Platform

Through extensive research and technological expertise, our platform is dedicated to the identification and development of MGDs for previously "undruggable" targets. To this end, our platform is equipped with:

• Unique Molecular Glue Compound Library: Our team has designed and synthesized a proprietary library of MGDs, grounded in decades of research in protein ubiquitination and degradation. This library serves as a cornerstone for discovering novel drugs targeting a wide range of diseases.
• Advanced Screening Techniques: We utilize a combination of phenotypic assays, proteomics, and induced proximity screening methods to identify disease-relevant targets for MGDs. This approach enables the discovery of targets that were previously deemed "undruggable" by conventional small-molecule inhibitors or monoclonal antibodies.
• Targeting the Ubiquitin-Proteasome Pathway: The ubiquitin-proteasome pathway is a critical cellular mechanism for protein degradation. Within this pathway, E3 ligases play a pivotal role by facilitating the ubiquitination of target proteins, marking them for degradation. Our platform focuses on elucidating the mechanisms of various E3 ligases, enabling us to develop cutting-edge molecular glue solutions that exploit this pathway.
• Comprehensive Biological Support: In addition, we employ a wide array of validation methods, including cellular, biochemical, biophysical, and mouse genetics studies to support the development of MGDs. These techniques provide robust evidence for the biological relevance and therapeutic potential of molecular glue targets.
• Artificial Intelligence Integration: We also leverage AI and machine learning to support the development of MGDs. These technologies are used to identify potential molecular glue candidates, optimize their properties, and model their interactions with target proteins. AI-driven insights can drastically reduce the time and cost of drug discovery.

Two Strategies for Molecular Glue Discovery at Our Platform

01

Strategy 1: From Compound to Target

This strategy focuses on starting with a compound and identifying its corresponding biological target. By screening our molecular glue library against disease-relevant systems, we pinpoint the targets that these compounds degrade. This approach allows us to uncover novel mechanisms of action and expand the therapeutic potential of MGDs.

02

Strategy 2: From Target to Compound

In this approach, we begin with a pre-identified target and search for compounds that can act as MGDs. Using our advanced screening methods and proprietary database, we match targets with specific molecular glue candidates. This targeted approach ensures precision and efficiency in drug development.

Why Partner with Us?

• Expertise in Protein Degradation: Our platform is built upon years of research and expertise in the field of protein ubiquitination and degradation.
• Comprehensive Library and Databases: Our proprietary MGD library and target database provide unparalleled resources for discovering and developing molecular glue drugs.
• Cutting-Edge Technology: We integrate state-of-the-art techniques, including proteomics, biophysics, and genetic studies, into our discovery pipeline.
• Focus on Undruggable Targets: By targeting the undruggable targets, our platform addresses unmet medical needs and opens new therapeutic avenues for diseases that were previously considered intractable.

By leveraging advanced screening methods, a proprietary MGD library, and a deep understanding of the ubiquitin-proteasome system, we aim to revolutionize the treatment landscape for challenging diseases. Our commitment to innovation, collaboration, and excellence positions us at the forefront of molecular glue research. For more information, please feel free to contact us.

It should be noted that our service is only used for research, not for clinical use.